LEO Pharma gains access to Boehringer’s skin disease drug for €90m upfront
Spevigo is already approved in over 40 countries to treat generalised pustular psoriasis
Read More
Section: Sales
AbbVie gains rights to IGI’s phase 1 trispecific engager in deal worth over $1.9bn
ISB 2001 is in early-stage clinical development for relapsed/refractory multiple myeloma
Read More
Merck to expand respiratory disease portfolio with $10bn Verona acquisition
The deal includes a drug approved in the US for chronic obstructive pulmonary disease
Read More
AbbVie to expand immunology capabilities with $2.1bn Capstan acquisition
The deal includes a CAR-T therapy in phase 1 development for B cell-mediated autoimmune diseases
Read More
Novartis and ProFound enter cardiovascular disease collaboration worth $750m per target
The companies will aim to discover and develop new therapeutics for the group of disorders
Read More